newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results

– Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis – On track to report 12-month topline safety, biomarker, and clinical outcomes data from low-dose cohort of AXO-AAV-GM1 i